Free Trial
Notice: This company has been marked as potentially delisted and may not be actively trading.
NASDAQ:ADMS

Adamas Pharmaceuticals (ADMS) Stock Price, News & Analysis

Adamas Pharmaceuticals logo

About Adamas Pharmaceuticals Stock (NASDAQ:ADMS)

Key Stats

Today's Range
$8.22
$8.22
50-Day Range
$7.97
$8.23
52-Week Range
$4.02
$9.15
Volume
N/A
Average Volume
692,487 shs
Market Capitalization
$376.37 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

Adamas Pharmaceuticals, Inc. engages in discovery and development of chrono-synchronous therapies for chronic neurologic disorders. Its products include GOCOVRI, ADS-5012, ADS-4101, and Namzaric. GOCOVRI is indicated for the treatment of dyskinesia in patients with Parkinson's disease receiving levodopa-based therapy. ADS-5102 is a treatment for walking impairment in patients with multiple sclerosis. ADS-401 treats partial onset seizures in patients with epilepsy. Namzaric is a drug treatment for moderate to severe Alzheimer's disease. The company was founded by Gregory T. Went on November 15, 2000 and is headquartered in Emeryville, CA.

Receive ADMS Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Adamas Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

ADMS Stock News Headlines

[625,000% Gain] – Are You Ready for the Next Altcoin Boom?
All of our key indicators are flashing the same signal: an altcoin season is fast approaching. And if you know anything about crypto, you know that altcoin seasons are where some of the biggest gains happen.
Adamas One Corp (JEWL)
See More Headlines

ADMS Stock Analysis - Frequently Asked Questions

Adamas Pharmaceuticals, Inc. (NASDAQ:ADMS) released its earnings results on Thursday, November, 11th. The specialty pharmaceutical company reported ($0.43) earnings per share for the quarter, missing analysts' consensus estimates of ($0.22) by $0.21. The specialty pharmaceutical company earned $25.90 million during the quarter, compared to the consensus estimate of $25.07 million.

Based on aggregate information from My MarketBeat watchlists, some other companies that Adamas Pharmaceuticals investors own include Rite Aid (RAD), VBI Vaccines (VBIV), Amarin (AMRN), Agile Therapeutics (AGRX), Dynavax Technologies (DVAX), TherapeuticsMD (TXMD) and Exelixis (EXEL).

Company Calendar

Last Earnings
11/11/2021
Today
11/23/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical Preparations
Sub-Industry
N/A
Current Symbol
NASDAQ:ADMS
Employees
138
Year Founded
2002

Profitability

Net Income
$-57,400,000.00
Pretax Margin
-71.11%

Debt

Sales & Book Value

Annual Sales
$74.46 million
Book Value
($0.47) per share

Miscellaneous

Free Float
37,133,000
Market Cap
$376.37 million
Optionable
Optionable
Beta
2.82

Social Links

7 Stocks to Own Before the 2024 Election Cover

Looking to avoid the hassle of mudslinging, volatility, and uncertainty? You'd need to be out of the market, which isn’t viable. So where should investors put their money? Find out with this report.

Get This Free Report

This page (NASDAQ:ADMS) was last updated on 11/23/2024 by MarketBeat.com Staff
From Our Partners